[Skip to Content]
[Skip to Content Landing]
May 26, 2004

Measuring the Effects of Therapy in Parkinson Disease

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(20):2430-2431. doi:10.1001/jama.291.20.2430-b

To the Editor: In their article about neuroprotection in Parkinson disease (PD), Drs Schapira and Olanow1 briefly discussed our phase 2 study of coenzyme Q10 in early PD.2 We believe that in their statement that "activity of daily living scores improved significantly following introduction of the drug, raising the possibility that an unanticipated symptomatic effect might also have confounded interpretation," the authors have overstated the significance of one item in the results.

First Page Preview View Large
First page PDF preview
First page PDF preview